Novo Nordisk (NVO) Stock: Oral Wegovy Pill Filing in China Imminent

Key Takeaways

• Novo Nordisk will submit its oral Wegovy formulation to Chinese authorities “within a few months,” according to CEO
• The announcement marks CEO Mike Doustdar’s inaugural China trip following his appointment in August
• Rival Eli Lilly gained first-mover advantage by filing orforglipron with Chinese regulators in late 2025
• China patent protection for semaglutide lapsed in March, opening doors for generic manufacturers by mid-2026
• NVO stock shows modest 0.09% gain and holds a Hold rating with analysts targeting $46 per share

Novo Nordisk is making its move in China’s burgeoning oral obesity treatment sector, with Chief Executive Mike Doustdar revealing plans to seek regulatory clearance for the company’s Wegovy tablet formulation “very soon — a few months.”

Novo Nordisk A/S, NVO

Doustdar disclosed the timeline during his maiden visit to China after assuming leadership last August. Shares of NVO were marginally higher by 0.09% following the disclosure.

China represents the globe’s second-biggest pharmaceutical marketplace, with GLP-1 obesity medications emerging as one of its most dynamic therapeutic categories. First-quarter GLP-1 product sales through platforms including Alibaba and JD.com reached approximately 1.4 billion yuan ($207 million), data from Jefferies indicates.

Novo maintains existing market presence. Chinese regulators granted approval for its injectable Wegovy formulation in the middle of 2024. Introducing an oral alternative would provide the Danish pharmaceutical giant with an additional pathway, appealing to consumers who favor tablets over needles.

However, the company trails its primary competitor. Eli Lilly filed its once-daily oral candidate orforglipron with Chinese regulatory bodies in late 2025, securing a temporal advantage in the approval process. Lilly currently markets Mounjaro throughout China for both Type 2 diabetes management and weight reduction.

Generic Competitors Preparing to Enter

The challenge extends beyond Lilly. Semaglutide — the core compound in Wegovy and Ozempic — saw its Chinese patent expire in March. While Novo maintains regulatory data exclusivity through early next year, generic alternatives are anticipated to reach the market around Q2 2026.

Doustdar recognized the incoming challenge but emphasized production complexity as a defensive moat. “Not many of our competitors will be able to reach that level, have the capabilities,” he stated, highlighting the difficulties inherent in large-scale oral formulation manufacturing.

To maintain competitiveness against generic entrants and domestic imitation products, Novo has implemented price reductions for Wegovy across select Chinese regions.

Pfizer and domestic pharmaceutical company Innovent Biologics have likewise penetrated the space, although precise market distribution data for China remains opaque. Neither Innovent nor Lilly provides Chinese revenue breakdowns.

Novo introduced its Wegovy pill in American markets this year after securing expedited clearance there and in Britain. Lilly received U.S. regulatory approval for orforglipron in April.

Wall Street’s Perspective

Among equity analysts, NVO maintains a Hold consensus classification based on three uniform Hold recommendations on TipRanks. The mean price objective stands at $46, suggesting approximately 4.7% appreciation potential from present trading levels.

For the year-to-date period, NVO has declined 11.4%, mirroring investor apprehension regarding patent vulnerabilities, pricing headwinds, and intensifying competitive dynamics.

The China regulatory submission is anticipated within the coming months, per Doustdar’s indication.